Clinical Report: RSV Vaccine Eligibility Expands

Overview

The FDA has expanded the indication for the RSV vaccine Arexvy to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease. This decision is based on findings from a phase 3b trial demonstrating a noninferior immune response in this younger high-risk group compared to older adults.

Background

Respiratory syncytial virus (RSV) poses a significant health burden, particularly among adults with chronic medical conditions. The recent expansion of vaccine eligibility is crucial as it addresses the substantial number of adults under 50 who are at risk for severe RSV infections. Understanding and preventing RSV-related morbidity in this population is essential for improving public health outcomes.

Data Highlights

The phase 3b trial enrolled 1,458 participants across 52 locations in 6 countries, demonstrating a noninferior immune response in adults aged 18 to 49 years at increased risk for RSV-related lower respiratory tract disease.

Key Findings

• The RSV vaccine Arexvy is now approved for adults aged 18 to 49 years at increased risk for severe RSV disease.
• Approximately 21 million adults under 50 years in the US have at least one risk factor for severe RSV infection.
• RSV is estimated to cause 17,000 hospitalizations and nearly 2 million outpatient visits annually among adults aged 18 to 49 years.
• The most common adverse events reported were mild to moderate, including injection site pain and fatigue.
• The vaccine's safety profile aligns with previous phase 3 clinical trials.

Clinical Implications

Healthcare providers should consider the expanded eligibility for the RSV vaccine when assessing patients aged 18 to 49 with chronic medical conditions. Increased awareness and vaccination efforts are necessary to reduce the burden of RSV in this high-risk population.

Conclusion

The expansion of RSV vaccine eligibility represents a significant advancement in preventing severe disease among younger adults at risk. Continued monitoring of vaccine uptake and effectiveness will be essential for optimizing public health strategies.

References

1. GSK, GSK US, 2023 -- GSK presents positive data for AREXVY, indicating protection over three RSV seasons
2. Infection, 2023 -- 2023 Recommendations for RSV Vaccination Approaches in High-Risk Populations: A Joint Position Statement from Prominent German Medical Associations
3. The Journal of Infectious Diseases, 2023 -- Incidence of Respiratory Syncytial Virus-Associated Hospitalization Among Adults in Ontario, Canada, 2017–2019
4. Open Forum Infectious Diseases, 2023 -- Limited Vaccination Rates and Health Disparities for Respiratory Syncytial Virus Among Veterans in the United States
5. AREXVY | FDA
6. Open Forum Infectious Diseases — Evaluating the Risk of Respiratory Syncytial Virus in Adults: Considerations for Vaccine Guidelines Across Age Groups
7. FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy
8. AREXVY | FDA
9. GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons | GSK US